On May 27, 2022 OriCell Therapeutics Co., Ltd (OriCell), a leading innovative biopharmaceutical company pioneering novel oncology cell therapies for the unmet medical needs in in hematology and oncology, reported that an abstract detailing data from a Phase I study(POLARIS) evaluating OriCAR-017 in patients with Relapsed/Refractory Multiple Myeloma will be presented an oral session at the upcoming 2022 ASCO (Free ASCO Whitepaper) Annual Meeting on Sunday, June 5th (Press release, OriCell Therapeutics, MAY 27, 2022, View Source;oricell-therapeutics-announces-oral-presentation-at-2022-asco-annual-meeting-detailing-results-from-phase-i-polaris-study-of-oricar-017-301556668.html [SID1234615218]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
About POLARIS Study
This is a Phase I first-in-human study of OriCAR-017 in patients with Relapsed/Refractory Multiple Myeloma (NCT05016778).
POLARIS study enrolled adults with measurable MM, R/R or intolerant to established MM therapies, prior BCMA-targeted therapy allowed. OriCAR-017 was administered by a single infusion at 3 dose cohorts to 9 patients. In all patients, majority of AEs were transient, manageable, and reversible. CRS only in Grade 1or2. No DLT, Neurotoxicities been observed. No death due to AE. Responses were durable and deepened overtime with 100% ORR and 100% MRD negative rate, including BCMA CAR-T relapsed patients, all patients are progression free and followed without additional therapy at the cutoff date. Updated data will be oral presented at the upcoming 2022 ASCO (Free ASCO Whitepaper) Annual Meeting, in McCormick Place, Chicago, IL on June 3-7, 2022.
Details for the abstract as below:
Abstract ID: 8004
Abstract Title: Phase I open-label single arm study of GPRC5D CAR T-cells (OriCAR-017) in patients with relapsed/refractory multiple myeloma (POLARIS)
Session Type/Title: Oral Abstract Session/ Hematologic Malignancies—Plasma Cell Dyscrasia
Session Date and Time: Sunday, June 5, 2022, 8:00 AM-11:00 AM CDT
Link：View Source
About OriCAR Technology Platform
An autologous GPRC5D-directed CAR T cell with a memory and anti-exhaustion T cells phenotype on the basis of the standard second generation CAR T cell, which improves the expansion and durability of CAR-T post-transfusion.